+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report by Workflow, by Technology (WGS, WES), by Application (Screening, Companion Diagnostics), by End-use, and Segment Forecasts, 2021-2028

  • ID: 5415632
  • Report
  • February 2021
  • Region: Global
  • 155 Pages
  • Grand View Research

FEATURED COMPANIES

  • Agilent Technologies
  • Eurofins Scientific S.E.
  • Foundation Medicine Inc.
  • Myriad Genetics, Inc.
  • Paradigm Diagnostics, Inc
  • Perkin Elmer

The global clinical oncology next generation sequencing market size is expected to reach USD 892.61 million by 2028 registering a CAGR of 14.70%. Technological advancements in next-generation sequencing coupled with high adoption of companion diagnostics and personalized medicine drive the global market growth.





In addition, a rise in the utility of next generation sequencing (NGS) for liquid biopsy is expected to increase revenue generation in the market. NGS is employed to sequence circulating tumor DNA (ctDNA) for the analysis of liquid biopsy samples. This leads to efficient molecular profiling of tumors, which, in turn, facilitates real-time, non-invasive monitoring of tumors.

Moreover, a rise in market competitiveness, growth in oncology diagnostics spending, and increasing research activities to develop solutions that can potentially be used for clinical oncology drive market progression. For instance, in January 2021, Spectrum Solutions, LLC collaborated with the UCLA School of Dentistry on saliva-based NGS liquid biopsy research, which would be used for early diagnosis of Non-Small Cell Lung Cancer (NSCLC).

North America dominated the global market in 2020 owing to multiple initiatives taken by various government bodies in the region to screen and prevent cancer, such as Cancer Prevention and Control Research Network, a flagship program by the CDC. The Asia Pacific is projected to be the fastest-growing regional market over the forecast period owing to continuous reforms in the pharmaceutical and life sciences industries in the region.

Key players in this market have undertaken strategic alliances to strengthen their market position. For example, in March 2020, Thermo Fisher Scientific signed an agreement with Janssen Biotech, Inc. for the development of CDx for tumor management. Under the agreement, Janssen Research & Development, LLC would validate multiple biomarkers to be used with Thermo Fisher's Oncomine Dx target test for identification of patients with NSCLC


Clinical Oncology NGS Market Report Highlights

  • Targeted sequencing & resequencing accounted for the largest market share in 2020 owing to the high adoption of targeted gene panels for oncology diagnostics
  • Moreover, the discovery of novel cancer biomarkers further boosts the development of targeted sequencing oncology panels
  • Whole-Genome Sequencing (WGS) is projected to register the fastest growth rate from 2021 to 2028 as the technology offers a complete genomic survey of the tumor genome
  • This helps in the generation of a detailed map of indels, copy number changes, Single Nucleotide Variations (SNV), and complex structural rearrangements with a single assay
  • Companion diagnostics is projected to be the fastest-growing application segment from 2021 to 2028 owing to the high adoption and benefits offered by the technology
  • Therefore, major market participants focus on innovative R&D in companion diagnostics to gain approval for novel tests
  • For instance, in August 2020, the FDA approved Guardant360 CDx assay; an NGS-based liquid biopsy CDx to identify Epidermal Growth Factor Receptor (EGFR) gene mutations in metastatic NSCLC


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Clinical Oncology Next Generation Sequencing Market

What is the estimated value of the Clinical Oncology Next Generation Sequencing Market?

The Clinical Oncology Next Generation Sequencing Market was estimated to be valued at $330.2 Million in 2021.

What is the growth rate of the Clinical Oncology Next Generation Sequencing Market?

The growth rate of the Clinical Oncology Next Generation Sequencing Market is 14.7%, with an estimated value of $892.6 Million by 2028.

What is the forecasted size of the Clinical Oncology Next Generation Sequencing Market?

The Clinical Oncology Next Generation Sequencing Market is estimated to be worth $892.6 Million by 2028.

Who are the key companies in the Clinical Oncology Next Generation Sequencing Market?

Key companies in the Clinical Oncology Next Generation Sequencing Market include Illumina, Inc., F. Hoffmann, La Roche Ltd, Agilent Technologies, Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Beijing Genomics Institute (BGI), Qiagen NV and Pacific Bioscience, Inc..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Agilent Technologies
  • Eurofins Scientific S.E.
  • Foundation Medicine Inc.
  • Myriad Genetics, Inc.
  • Paradigm Diagnostics, Inc
  • Perkin Elmer

Chapter 1 Executive Summary
1.1 Market Snapshot
Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Information or Data Analysis
2.3 Market Formulation & Validation
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Business segment trends
3.2.1 Penetration & Growth Prospect Mapping For Application, 2020
3.2.2 Penetration & Growth Prospect Mapping For Prominent Industry Players, 2020
3.3 Market variables analysis
3.3.1Market driver analysis
3.3.1.1 Decrease in costs for genetic sequencing
3.3.1.2 Advancements in the field of personalized medicine
3.3.1.3 Rise in competition amongst prominent market entities
3.3.1.4 Growing healthcare expenditure triggering the development of effective PM diagnostic & therapeutic procedure for cancer
3.3.1.5 Rise in prevalence of cancer
3.3.1.6 Growing adoption of NGS over single gene testing
3.3.2 Market restraint analysis
3.3.2.1 Lack of computational efficiency for data management
3.3.2.2 Non-value based NGS reimbursement policy
3.4 Business environment analysis tools
3.4.1 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.4.2Porter’s five forces analysis
3.5 Impact of COVID-19 on Market Growth
3.6 Next-Generation Sequencing Reimbursement Environment
3.7 Regulatory and Political Environment
Chapter 4 Competitive & Vendor Landscape
4.1 Strategy Framework
4.2 Market Participation Categorization
Chapter 5 Clinical Oncology Next Generation Sequencing Market Categorization: Technology Estimates & Trend Analysis
5.1 Clinical Oncology NGS Market: Technology movement analysis
5.2 Whole Genome Sequencing
5.2.1Whole genome sequencing for clinical oncology market, 2017 - 2028 (USD Million)
5.3 Whole Exome Sequencing
5.3.1 Whole exome sequencing for clinical oncology market, 2017 - 2028 (USD Million)
5.4 Targeted Sequencing & Resequencing
5.4.1 Targeted sequencing and resequencing for clinical oncology market, 2017 - 2028 (USD Million)
Chapter 6 Clinical Oncology Next Generation Sequencing Market Categorization: Workflow Estimates & Trend Analysis
6.1 Clinical Oncology NGS Market: Workflow Movement Analysis
6.2 NGS Pre-Sequencing
6.2.1 NGS pre-sequencing for clinical oncology market, 2017 - 2028 (USD Million)
6.3 NGS Sequencing
6.3.1 NGS sequencing for clinical oncology market, 2017 - 2028 (USD Million)
6.4 NGS Data Analysis
6.4.1 NGS data analysis for clinical oncology market, 2017 - 2028 (USD Million)
Chapter 7 Clinical Oncology Next Generation Sequencing Market Categorization: Application Estimates & Trend Analysis
7.1 Clinical Oncology NGS Market: Application Movement Analysis
7.2 Screening
7.2.1 Screening clinical oncology NGS market, 2017 - 2028 (USD Million)
7.2.2 Sporadic Cancer
7.2.2.1 Sporadic cancer screening clinical oncology NGS market, 2017 - 2028 (USD Million)
7.2.3Inherited cancer
7.2.3.1 Inherited cancer screening clinical oncology NGS market, 2017 - 2028 (USD Million)
7.3 Companion Diagnostics
7.3.1 Companion diagnostics clinical oncology NGS market, 2017 - 2028 (USD Million)
7.4 Other Diagnostics
7.4.1 Other diagnostics clinical oncology NGS market, 2017 - 2028 (USD Million)
Chapter 8 Clinical Oncology Next Generation Sequencing Market Categorization: End Use Estimates & Trend Analysis
8.1 Clinical Oncology NGS Market: End Use Movement Analysis
8.2 Hospitals
8.2.1 Hospitals clinical oncology NGS market, 2017 - 2028 (USD Million)
8.3 Clinics
8.3.1 Clinics clinical oncology NGS market, 2017 - 2028 (USD Million)
8.4 Laboratories
8.4.1 Laboratories clinical oncology NGS market, 2017 - 2028 (USD Million)
Chapter 9 Clinical Oncology Next Generation Sequencing Market Categorization: Regional Estimates & Trend Analysis, by Technology, Workflow, Application, & End Use
9.1 Clinical Oncology NGS Market Share By Regional, 2018 & 2025
9.2 North America
9.2.1 North America clinical oncology NGS market, 2017 - 2028 (USD Million)
9.2.2 The U.S.
9.2.2.1 The U.S. clinical oncology NGS market, 2017 - 2028 (USD Million)
9.2.3Canada
9.2.3.1Canada clinical oncology NGS market, 2017 - 2028 (USD Million)
9.3 Europe
9.3.1 Europe clinical oncology NGS market, 2017 - 2028 (USD Million)
9.3.2 Germany
9.3.2.1 Germany clinical oncology NGS market, 2017 - 2028 (USD Million)
9.3.3 The U.K.
9.3.3.1 The U.K. clinical oncology NGS market, 2017 - 2028 (USD Million)
9.3.4 France
9.3.4.1 France clinical oncology NGS market, 2017 - 2028 (USD Million)
9.3.5 Italy
9.3.5.1 Italy clinical oncology NGS market, 2017 - 2028 (USD Million)
9.3.6Spain
9.3.6.1Spain clinical oncology NGS market, 2017 - 2028 (USD Million)
9.4 Asia Pacific
9.4.1Asia-Pacific clinical oncology NGS market, 2017 - 2028 (USD Million)
9.4.2Japan
9.4.2.1 Japan clinical oncology NGS market, 2017 - 2028 (USD Million)
9.4.3China
9.4.3.1 China clinical oncology NGS market, 2017 - 2028 (USD Million)
9.4.4India
9.4.4.1 India clinical oncology NGS market, 2017 - 2028 (USD Million)
9.4.5South Korea
9.4.5.1 South Korea clinical oncology NGS market, 2017 - 2028 (USD Million)
9.4.6Australia
9.4.6.1 Australia clinical oncology NGS market, 2017 - 2028 (USD Million)
9.5 Latin America
9.5.1 Latin America clinical oncology NGS market, 2017 - 2028 (USD Million)
9.5.2Brazil
9.5.2.1 Brazil clinical oncology NGS market, 2017 - 2028 (USD Million)
9.5.3Mexico
9.5.3.1 Mexico clinical oncology NGS market, 2017 - 2028 (USD Million)
9.6 Middle East & Africa (MEA)
9.6.1 Middle East & Africa clinical oncology NGS market, 2017 - 2028 (USD Million)
9.6.2 South Africa
9.6.2.1 South Africa clinical oncology NGS market, 2017 - 2028 (USD Million)
9.6.3 Saudi Arabia
9.6.3.1 Saudi Arabia clinical oncology NGS market, 2017 - 2028 (USD Million)
Chapter 10 Clinical Oncology NGS Market: Company Profiles
10.1 Key Companies Profiled
10.2 Illumina, Inc.
10.2.1 Company overview
10.2.1.1Financial performance
10.2.2 Product benchmarking
10.2.3 Strategic initiatives
10.3 F. Hoffmann-La Roche Ltd
10.3.1 Company overview
10.3.1.1Financial performance
10.3.2 Product benchmarking
10.3.3 Strategic initiatives
10.4 Agilent Technologies
10.4.1 Company overview
10.4.2 Financial performance
10.4.3 Product benchmarking
10.4.4 Strategic initiatives
10.5 Thermo Fisher Scientific Inc.
10.5.1 Company overview
10.5.2 Financial performance
10.5.3 Product benchmarking
10.5.4 Strategic initiatives
10.6 Myriad Genetics, Inc.
10.6.1 Company overview
10.6.2 Financial performance
10.6.3 Product benchmarking
10.6.4 Strategic initiatives
10.7 Beijing Genomics Institute (BGI)
10.7.1Company overview
10.7.2Financial performance
10.7.3Product benchmarking
10.7.4Strategic initiatives
10.8 Qiagen NV
10.8.1 Company overview
10.8.2 Financial performance
10.8.3 Product benchmarking
10.8.4 Strategic initiatives
10.9 Perkin Elmer, Inc.
10.9.1 Company overview
10.9.2 Financial performance
10.9.3 Product benchmarking
10.9.4 Strategic initiatives
10.10 Pacific Bioscience, Inc.
10.10.1 Company overview
10.10.2 Financial performance
10.10.3 Product benchmarking
10.10.4 Strategic initiatives
10.11 Partek, Inc.
10.11.1 Company overview
10.11.2 Financial performance
10.11.3 Product benchmarking
10.11.4 Strategic initiatives
10.12 Foundation Medicine Inc.
10.12.1 Company overview
10.12.2 Financial performance
10.12.3 Product benchmarking
10.12.4 Strategic Initiatives
10.13 Oxford Nanopore Technologies Ltd.
10.13.1 Company overview
10.13.2 Financial performance
10.13.3 Product benchmarking
10.13.4 Strategic Initiatives
10.14 Paradigm Diagnostics, Inc
10.14.1 Company overview
10.14.2 Financial performance
10.14.3 Product benchmarking
10.14.4 Strategic initiatives
10.15 Caris Life Sciences
10.15.1 Company overview
10.15.2 Financial performance
10.15.3 Product benchmarking
10.15.4 Strategic Initiatives
10.16 Eurofins Scientific S.E.
10.16.1 Company overview
10.16.2 Financial performance
10.16.3 Product benchmarking
10.16.4 Strategic initiatives
10.17 Perkin Elmer
10.17.1 Company overview
10.17.2 Financial performance
10.17.3 Product benchmarking
10.17.4 Strategic initiatives
List of Tables
Table 1 Healthcare expenditure levels, 2012
Table 2 Cancer Incidence and Mortality, By Region, 2018
Table 3 Genes associated with breast and ovarian cancer that can be sequenced by NGS panel
Table 4 FDA-Approved NGS Tumour-Profiling Tests for Companion Diagnostics
Table 5 Gene-panels used in clinics for Hereditary Breast/Ovarian Cancer (HBOC)
Table 6 North America clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 7 North America clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 8 North America clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 9 North America clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 10 North America clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 11 The U.S. clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 12 The U.S. clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 13 The U.S. clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 14 The U.S. clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 15 The U.S. clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 16 Canada clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 17 Canada clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 18 Canada clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 19 Canada clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 20 Canada clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 21 Europe clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 22 Europe clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 23 Europe clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 24 Europe clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 25 Europe clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 26. Germany clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 27. Germany clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 28. Germany clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 29. Germany clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 30. Germany clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 31. The U.K. clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 32. The U.K. clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 33. The U.K. clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 34. The U.K. clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 35. The U.K. clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 36. France clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 37. France clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 38. France clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 39. France clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 40. France clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 41. Italy clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 42. Italy clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 43. Italy clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 44. Italy clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 45. Italy clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 46. Spain clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 47. Spain clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 48. Spain clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 49. Spain clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 50. Spain clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 51. Asia-Pacific clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 52. Asia-Pacific clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 53. Asia-Pacific clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 54. Asia-Pacific clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 55. Asia-Pacific clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 56. Japan clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 57. Japan clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 58. Japan clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 59. Japan clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 60. Japan clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 61. China clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 62. China clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 63. China clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 64. China clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 65. China clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 66. India clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 67. India clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 68. India clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 69. India clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 70. India clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 71. South Korea clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 72. South Korea clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 73. South Korea clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 74. South Korea clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 75. South Korea clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 76. Australia clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 77. Australia clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 78. Australia clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 79. Australia clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 80. Australia clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 81. Latin America clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 82. Latin America clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 83. Latin America clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 84. Latin America clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 85. Latin America clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 86. Brazil clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 87. Brazil clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 88. Brazil clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 89. Brazil clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 90. Brazil clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 91. Mexico clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 92. Mexico clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 93. Mexico clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 94. Mexico clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 95. Mexico clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 96. Middle East & Africa clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 97. Middle East & Africa clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 98. Middle East & Africa clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 99. Middle East & Africa clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 100. Middle East & Africa clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 101. South Africa clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 102. South Africa clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 103. South Africa clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 104. South Africa clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 105. South Africa clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
Table 106. Saudi Arabia clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
Table 107. Saudi Arabia clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
Table 108. Saudi Arabia clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 109. Saudi Arabia clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 110. Saudi Arabia clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
List of Figures
Fig. 1 Market snapshot
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value chain based sizing & forecasting
FIG. 7 QFD modelling for market share assessment
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Penetration & growth prospect mapping for application, 2020
FIG. 11 Penetration & growth prospect mapping for prominent industry players, 2020
FIG. 12 Market driver relevance analysis (Current & future impact)
FIG. 13 Cost per raw mega base (Mb) of DNA sequence (USD)
FIG. 14 Cost per genome
FIG. 15 Expected rise in expenditure for cancer treatment (USD Billion)
FIG. 16 Number of new cancer cases in the World, 2018
FIG. 17 Market restraint relevance analysis (Current & future impact)
FIG. 18 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 19 Porter’s Five Forces Analysis
FIG. 20 Strategy framework
FIG. 21 Participant categorization
FIG. 22 Clinical oncology NGS market: Technology outlook key takeaways
FIG. 23 Clinical oncology NGS market: Technology movement analysis
FIG. 24 Whole genome sequencing for clinical oncology market, 2017 - 2028 (USD Million)
FIG. 25 Whole exome sequencing for clinical oncology market, 2017 - 2028 (USD Million)
FIG. 26 Targeted sequencing and resequencing for clinical oncology market, 2017 - 2028 (USD Million)
FIG. 27 Clinical oncology NGS market: Workflow outlook key takeaways
FIG. 28 Clinical oncology NGS market: Workflow movement analysis
FIG. 29 NGS pre-sequencing for clinical oncology market, 2017 - 2028 (USD Million)
FIG. 30 NGS sequencing for clinical oncology market, 2017 - 2028 (USD Million)
FIG. 31 NGS data analysis for clinical oncology market, 2017 - 2028 (USD Million)
FIG. 32 Clinical oncology NGS market: Application outlook key takeaways
FIG. 33 Clinical oncology NGS market: Application movement analysis
FIG. 34 Screening clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 35 Sporadic cancer screening clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 36 Lifetime cancer risks for common cancers
FIG. 37 Inherited cancer screening clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 38 Companion diagnostics clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 39 Other diagnostics clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 40 Clinical oncology NGS market: End use outlook key takeaways
FIG. 41 Clinical oncology NGS market: End use movement analysis
FIG. 42 Hospitals clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 43 Clinics clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 44 Laboratories clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 45 Regional market place: Key takeaway
FIG. 46 Clinical oncology NGS market: Regional outlook, 2018 & 2025
FIG. 47 North America clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 48 The U.S. clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 49 Canada clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 50 Europe clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 51 Germany clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 52 The U.K. clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 53 France clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 54 Italy clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 56 Asia-Pacific clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 57 Japan clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 58 China clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 55 Spain clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 59 India clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 60 South Korea clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 61 Australia clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 62 Latin America clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 63 Brazil clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 64 Mexico clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 65 Middle East & Africa clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 66 South Africa clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 67 Saudi Arabia clinical oncology NGS market, 2017 - 2028 (USD Million)
FIG. 68 Key companies profiled
Note: Product cover images may vary from those shown
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies
  • Thermo Fisher Scientific Inc.
  • Myriad Genetics, Inc.
  • Beijing Genomics Institute (BGI)
  • Qiagen NV
  • Perkin Elmer, Inc.
  • Pacific Bioscience, Inc.
  • Partek, Inc.
  • Foundation Medicine Inc.
  • Oxford Nanopore Technologies Ltd.
  • Paradigm Diagnostics, Inc
  • Caris Life Sciences
  • Eurofins Scientific S.E.
  • Perkin Elmer
Note: Product cover images may vary from those shown

Loading
LOADING...